Medipharm Labs (Otc) ( (MEDIF) ) has released its Q3 earnings. Here is a breakdown of the information Medipharm Labs (Otc) presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MediPharm Labs is a pharmaceutical company specializing in precision-based cannabinoids, focusing on the development and manufacture of purified, pharmaceutical-quality cannabis products for domestic and international medical markets.
In its latest earnings report for the third quarter of 2025, MediPharm Labs reported a 17% increase in revenue compared to the same period last year, reaching $11.4 million. The company highlighted significant growth in its international medical cannabis segment, which now accounts for 56% of total revenue, reflecting an 83% year-over-year increase.
Key financial metrics from the report include a cash balance increase to $10.6 million and a 19% reduction in operating expenses year-over-year. Despite a negative adjusted EBITDA of $1.1 million, the company showed improved cash management and strategic expansion in international markets, including the launch of new inhaler products in Australia.
Looking ahead, MediPharm Labs remains focused on enhancing its profitability profile by continuing to drive revenue growth and streamline expenses. The company is strategically positioned to capitalize on growth opportunities in the evolving medical cannabis industry.